Related Experiment Video
Updated: Jan 17, 2026
Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment
Published on: January 12, 2024
A novel non-steroidal treatment approach for moderate Atopic dermatitis in a 13-month-old infant using SNEPI: a case
Cheol-Jung Yang1,2, Sin-Hye Park3, Daewook Lee4
1Department of Orthopedic Surgery, Borntouch Orthopaedic Clinic, Seoul, Republic of Korea.
Insights
Sympathetic Nerve Entrapment Point Injection (SNEPI) offers a steroid-free treatment for pediatric atopic dermatitis (AD). This case study shows SNEPI effectively resolved AD symptoms and maintained remission for six years, highlighting its potential for autonomic modulation in skin disorders.
Area of Science:
- Dermatology
- Neurology
- Pediatrics
Background:
- Atopic dermatitis (AD) is a prevalent chronic inflammatory skin condition in infants.
- Current treatments like topical corticosteroids have limitations, necessitating alternative therapies.
Purpose of the Study:
- To evaluate the efficacy and safety of Sympathetic Nerve Entrapment Point Injection (SNEPI) for pediatric atopic dermatitis.
- To explore the role of autonomic modulation in managing inflammatory skin disorders.
Main Methods:
- A case study of a 13-month-old male with moderate AD refractory to standard treatments.
- SNEPI administered bilaterally at the T7 paraspinal level with normal saline weekly for three sessions.
- Clinical outcomes monitored during treatment and over a six-year follow-up.
Main Results:
- Complete resolution of pruritus and normalization of sleep after the first treatment.
- Achieved complete remission of skin lesions without corticosteroids by the third session.
- Maintained stable skin with occasional mild pruritus over a six-year follow-up period.
Conclusions:
- SNEPI shows potential as a safe, effective, and steroid-free neuromodulatory treatment for pediatric AD.
- Supports the hypothesis that autonomic modulation can benefit inflammatory skin conditions.
- Further clinical studies are needed to confirm SNEPI's broader applicability in pediatric dermatology.
Objectives:
Atopic dermatitis (AD) is a chronic inflammatory skin condition with increasing prevalence in infancy. Standard treatments rely heavily on topical corticosteroids, but concerns about long-term side effects and limited efficacy in some cases highlight the need for alternative therapeutic strategies.
Methods:
We present a 13-month-old male with moderate AD refractory to moisturizers and hydrocortisone ointments. Sympathetic Nerve Entrapment Point Injection (SNEPI) was administered bilaterally at the T7 paraspinal level using 1 mL of normal saline once weekly for three sessions. Clinical outcomes were monitored during treatment and over a six-year follow-up period.
Results:
Pruritus resolved and sleep normalized after the first treatment. By the third session, complete remission of skin lesions was achieved without corticosteroid use, with no recurrence observed during four weeks of follow-up. During a six-year follow-up, the child maintained stable skin with only occasional mild pruritus, suggesting sustained therapeutic benefit.
Conclusions:
This case demonstrates the potential of SNEPI as a safe, effective, and steroid-free neuromodulatory treatment for pediatric AD, supporting the role of autonomic modulation in inflammatory skin disorders. Further clinical studies are warranted to evaluate the broader applicability of SNEPI in pediatric dermatology.
More Related Videos
06:47Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
Published on: September 27, 2017
09:32Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
Related Concept Videos
01:19Clinical Applications of Epidermal Stem Cells
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...